Peptides: The Science, Uses & Safety — A Masterclass with Dr. Abud Bakri
Dr. Abud Bakri, an internal medicine physician, joins Andrew Huberman for an encyclopedic deep dive into the peptide landscape, spanning BPC-157, GLP-1 agonists, thymosin, Russian bioregulators, GHK-copper, and growth hormone secretagogues. A key organizing principle is whether a peptide has a known receptor, which determines its clinical predictability and safety profile. The episode makes clear that peptides are adjuncts to — not substitutes for — foundational health behaviors such as sleep, morning light, and an unprocessed diet.
Overview
Andrew Huberman hosts Dr. Abud Bakri, a 33-year-old internal medicine physician, in a nearly three-hour masterclass on peptides covering history, mechanisms, clinical use, and safety. The discussion opens with a foundational classification: peptides with known receptors (like GLP-1 agonists) have predictable, well-studied effects, while receptor-orphan peptides (like BPC-157 or epitalon) act through less-understood mechanisms including epigenetic modulation of DNA chromatin.
BPC-157, a 15-amino-acid peptide isolated from human gastric juice by Croatian researchers in 1991, is explored in depth for tissue repair, gut healing, and neural effects; animal data is extensive and reveals no identifiable LD50, but only a single formal human trial exists. The Russian bioregulator peptides — including epitalon and pinealon (EDR) — developed by Dr. Vladimir Khavinson are examined for telomere extension, cognitive support, and REM sleep enhancement. Thymosin alpha-1 and TB-500 (thymosin beta-4) are discussed for immune modulation and tissue repair, with the thymus positioned as an underappreciated aging clock whose involution correlates with immune decline.
GHK-copper is reviewed as a bidirectional collagen modulator with strong topical evidence for skin rejuvenation and emerging interest for lung repair. Growth hormone secretagogues are presented with the caveat that elevated IGF-1 promotes tissue growth but may carry long-term longevity trade-offs. The episode concludes with GLP-1 agonists (semaglutide, tirzepatide, retatrutide) framed as transformative metabolic drugs that have legitimized public interest in injectable peptides, while stressing that sleep, morning light, unprocessed diet, and exercise remain non-negotiable foundations.
Key quotes
5People are now stacking their GLP-1 as their insulin sensitivity tool, their growth hormone, and their androgen modulation therapies as this trinity stack to get very fit, very healthy quickly.
Scientifically I would say [a peptide] is one of the languages of the human body. The body likes these different languages to communicate between cells.
In the literature, when it comes to the animal data, they've injected animals with a thousand times the dose of BPC with no real adverse effects. We don't even know the LD50 of BPC.
Our medical system was going to collapse on itself thanks to the obesity, pre-diabetes, diabetes epidemics. Now these GLP-1s are coming in and kind of transforming that phase of medicine.
There's no point in putting all these peptides in if someone's not having the basics in place — morning sunlight, sleep, darkness at night, good diet, minimally processed food.
Key ideas
9The receptor/no-receptor framework
The most clinically useful way to categorize peptides is whether they bind to a known receptor. Peptides with identified receptors (e.g., GLP-1 agonists) have predictable dose-response curves and robust regulatory-grade safety data, while those without known receptors (e.g., BPC-157, epitalon) may act through epigenetic modulation or protein scaffolding, making effects harder to predict and study formally.
BPC-157: from gastric juice to tissue repair
BPC-157 is a 15-amino-acid sequence discovered in 1991 by Croatian researchers who isolated it from the larger BPC protein in human gastric juice. Extensive animal studies demonstrate accelerated healing of tendons, ligaments, gut lining, and neural tissue, while the absence of a measurable LD50 underscores its unusually low acute toxicity profile in preclinical models.
Minimal human data despite enormous anecdotal use
Despite decades of animal research supporting BPC-157's regenerative properties, only a single formal human clinical trial exists. Explosive growth in human use is driven almost entirely by anecdotal reports and physician experimentation, making honest risk communication between clinician and patient especially important before any use.
Russian bioregulators as epigenetic switches
Dr. Vladimir Khavinson's Soviet-era research produced a class of di- and tripeptides (epitalon, pinealon/EDR, thymulin, cardiogen) that act by binding to specific grooves on DNA, opening or closing chromatin to regulate gene expression in a manner analogous to steroid hormones. Many show partial oral bioavailability at higher doses due to their very small size.
Pinealon/EDR and REM sleep enhancement
Pinealon (renamed EDR, a tripeptide) was developed by Khavinson for neuronal protection but has attracted attention for reports of dramatically enhanced REM sleep — an effect Khavinson himself never measured because sleep tracking did not exist in 1970s Soviet laboratories. The mechanism likely involves modulation of pineal gland function and the melatonin synthesis pathway.
Thymic involution as a core aging clock
The thymus trains T-cells to distinguish self from pathogen, peaks around puberty, and then progressively involutes, reducing T-cell output with age. This decline is linked to increased susceptibility to infections, autoimmunity, and cancer, and is further accelerated by chronic stress, sleep deprivation, and repeated infections.
Thymosin alpha-1 and TB-500 for immunity and repair
Thymosin alpha-1, once FDA-approved as Zadaxin for congenital thymic deficiency and approved in other countries for hepatitis adjuvant therapy, acts as accelerant for T-cell development and activation. TB-500 (thymosin beta-4) supports tissue repair via actin cytoskeleton remodeling and is a well-known doping agent in equine sports.
GHK-copper as a bidirectional collagen modulator
GHK-Cu simultaneously upregulates collagen synthesis and collagen breakdown, enabling proper tissue remodeling rather than fibrotic scarring. Topical formulations have outperformed retinol and vitamin C in some comparative trials for skin rejuvenation, while injectable forms are under early investigation for lung tissue repair in COPD and long COVID.
Growth hormone's double-edged longevity sword
Elevated growth hormone and its downstream mediator IGF-1 build muscle, restore thymic mass, and support lean body composition — but animal models of growth hormone deficiency consistently show extended lifespan, and larger dog breeds with higher IGF-1 levels live shorter lives. The debate over whether immune-surveillance benefits outweigh potential tumor-promoting effects remains unresolved.
Practical takeaways
7- 1
Always check for a known receptor before considering a peptide 4:42
Peptides with characterized receptors carry predictable effects and regulatory-grade safety data. Receptor-orphan peptides may offer real benefits but require accepting substantially greater uncertainty about mechanism and long-term risk.
- 2
Purity and sourcing are non-negotiable 37:01
Compounding pharmacies and gray-market suppliers vary enormously in quality; some products have been found to contain incorrect substances such as melanotan-2 instead of the intended peptide. Request independent HPLC or mass spectrometry certificates before using any compounded peptide.
- 3
BPC-157 use requires a frank physician conversation 19:56
The animal safety record is encouraging, but the absence of large human trials means BPC-157 remains investigational. Any use should involve transparent informed consent, defined therapeutic endpoints, and monitoring by a qualified clinician.
- 4
Thymosin alpha-1 may support immune resilience during high-exposure periods 1:37:56
Dr. Bakri uses 2.5 mg of thymosin alpha-1 twice weekly as a personal prophylactic during travel and hospital rotations. This is not FDA-approved for this indication and is presented as personal clinical experimentation, not a formal recommendation.
- 5
GLP-1 agonists are validated tools — but require clinical monitoring 2:23:04
Semaglutide, tirzepatide, and emerging retatrutide represent genuinely transformative medicines for metabolic disease. Long-term dependency, muscle loss if protein intake and resistance training are neglected, and the need for careful dose titration are the key practical concerns.
- 6
Foundational behaviors come before any peptide protocol 2:44:06
Sleep, morning light exposure, minimally processed food, and regular exercise are the non-negotiable baseline. No peptide protocol compensates for neglecting these, and several peptides (like pinealon) likely depend on intact circadian biology to produce their reported benefits.
- 7
Frame peptide use as a physician–patient partnership with clear endpoints 1:02:24
The most defensible and effective approach is a transparent clinician-patient conversation that honestly acknowledges what is and is not known, establishes clear monitoring endpoints, and avoids substituting online forum consensus for medical judgment.
Topics & chapters
15Introduction: the celebrity trinity and the episode's scope
Huberman opens with the growing trend of stacking GLP-1s, growth hormone modulators, and androgen therapies, then introduces Dr. Abud Bakri and maps the vast landscape of peptide science to be covered over nearly three hours.
What is a peptide? Defining the receptor/no-receptor framework
Dr. Bakri frames peptides as one of the body's cellular signaling languages and proposes a foundational two-category split — peptides with known receptors versus those without — explaining how this determines expected effects, predictability, and safety.
BPC-157: history and discovery from human gastric juice
A Croatian research team identified BPC-157 in 1991 as a 15-amino-acid sequence within human gastric juice, part of a broader discovery that nearly every organ produces a characteristic peptide signature important for local repair and function.
BPC-157 safety, adverse events, and the missing LD50
Animal studies using doses up to 1,000 times the therapeutic range reveal no identifiable lethal dose for BPC-157; adverse events in the literature are virtually nonexistent outside contamination issues. The single human trial conducted to date shows a favorable safety profile.
BPC-157 in sport, athlete recovery, and doping detection
Athletes have quietly experimented with BPC-157 for injury recovery partly because it was unknown to drug-testing authorities when first used, and its short half-life makes detection extremely difficult even with modern testing.
Sourcing, purity, and the compounding pharmacy quality spectrum
Raw peptide materials from a small number of international sources flow into vastly different quality tiers — from pharmaceutical-grade manufacturing down to gray-market research chemicals — and some users have unknowingly injected incorrect substances.
BPC-157 personal case studies and dosing considerations
Huberman describes injecting BPC-157 locally after a grade-2 tricep tear and reports unusually rapid recovery. Dr. Bakri discusses the clinical suspicion that underdosing — rather than peptide inefficacy — is the most common reason for disappointing results.
Legal and regulatory landscape for peptides in the US
BPC-157 occupies an ambiguous regulatory space — never approved as a drug yet sold as a supplement or research chemical — and the ideal clinical model involves transparent informed consent with defined endpoints monitored by a physician.
Russian bioregulators: Khavinson's epigenetic peptide library
Soviet scientist Dr. Vladimir Khavinson developed a library of di- and tripeptides (epitalon, pinealon/EDR, thymulin, cardiogen) acting as epigenetic switches by binding DNA chromatin grooves. Many are orally bioavailable at higher doses and have been studied in Russian human populations over decades.
Pinealon/EDR and REM sleep: mechanism and missing evidence
Pinealon (EDR) is linked in modern user reports to dramatic REM sleep enhancement, a finding absent from Khavinson's original research because sleep tracking technology did not exist in 1970s Soviet laboratories. Its mechanism likely involves pineal gland modulation and melatonin pathway support.
Thymus biology: the immune training ground that declines with age
The thymus trains T-cells to discriminate between self and pathogen and peaks around puberty before progressively involuting; chronic stress, poor sleep, and repeated infections accelerate its shrinkage, with downstream consequences for cancer surveillance and infection resistance.
Thymosin alpha-1 and TB-500: immune and tissue repair peptides
Thymosin alpha-1 acts as 'jet fuel' for T-cell development and activation and was once FDA-approved for congenital thymic deficiency; TB-500 (thymosin beta-4) supports repair via actin cytoskeleton remodeling and the TRIIM trial showed growth hormone can partially reverse thymic involution.
GHK-copper: collagen remodeling, skin rejuvenation, and emerging uses
GHK-Cu bidirectionally modulates collagen turnover for proper tissue remodeling, outperforms retinol and vitamin C in some skin trials, and is under early investigation for lung regeneration in COPD and long COVID — with topical use being the best-evidenced application.
Growth hormone, IGF-1, and the longevity trade-off debate
Growth hormone secretagogues improve lean mass and may regenerate thymic tissue, but animal models consistently link lower IGF-1 to longer lifespan; the debate over whether immune-surveillance benefits outweigh potential cancer risk in humans remains open and requires individualized risk assessment.
GLP-1 agonists: mechanism, metabolic revolution, and caveats
Semaglutide, tirzepatide, and retatrutide act on gut-brain GLP-1 receptors to suppress appetite and improve insulin sensitivity, achieving 20–30% body-weight reductions; discovered via Gila monster saliva peptides, they have transformed metabolic medicine but raise important questions about long-term use, muscle preservation, and clinical monitoring.